Annual Financials for EyePoint Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
7.54M | 5.86M | 20.37M | 34.44M | 36.94M | |
Sales Growth |
- | -22.32% | 247.76% | 69.10% | 7.27% | |
Cost of Goods Sold (COGS) incl. D&A |
815,000 | - | 5.15M | 8.28M | 10.64M | |
COGS excluding D&A |
- | - | 2.54M | 5.64M | 7.87M | |
Depreciation & Amortization Expense |
815,000 | 2.65M | 2.6M | 2.65M | 2.77M | |
Depreciation |
91,000 | 194,000 | 144,000 | 189,000 | 311,000 | |
Amortization of Intangibles |
724,000 | 2.46M | 2.46M | 2.46M | 2.46M | |
COGS Growth |
- | - | - | 60.95% | 28.40% | |
Gross Income |
6.72M | - | 15.22M | 26.15M | 26.3M | |
Gross Income Growth |
- | - | - | 71.86% | 0.57% | |
Gross Profit Margin |
- | - | - | - | 71.20% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
24.83M | 52.32M | 63.08M | 63.44M | 81.58M | |
Research & Development |
14.41M | 20.82M | 15.37M | 17.42M | 28.5M | |
Other SG&A |
10.42M | 31.5M | 47.71M | 46.02M | - | |
SGA Growth |
- | 110.74% | 20.56% | 0.58% | 28.58% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
472,000 | 18.89M | 3.81M | 905,000 | (2.07M) | |
EBIT after Unusual Expense |
(18.58M) | (68M) | (51.67M) | (38.2M) | (53.21M) | |
Non Operating Income/Expense |
91,000 | (18.89M) | - | - | - | |
Non-Operating Interest Income |
- | 734,000 | 1.05M | 58,000 | 292,000 | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | 3.28M | 6.18M | 7.26M | 5.5M | |
Interest Expense Growth |
- | - | 88.06% | 17.50% | -24.24% | |
Gross Interest Expense |
- | 3.28M | 6.18M | 7.26M | 5.5M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(18.49M) | (89.44M) | (56.79M) | (45.39M) | (58.42M) | |
Pretax Income Growth |
- | -383.85% | 36.50% | 20.07% | -28.69% | |
Pretax Margin |
- | - | - | - | -158.14% | NA |
Income Tax |
- | - | - | - | - | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(18.49M) | (89.44M) | (56.79M) | (45.39M) | (58.42M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(18.49M) | (89.44M) | (56.79M) | (45.39M) | (58.42M) | |
Net Income Growth |
- | -383.85% | 36.50% | 20.07% | -28.69% | |
Net Margin Growth |
- | - | - | - | -158.14% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(18.49M) | (89.44M) | (56.79M) | (45.39M) | (58.42M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(18.49M) | (89.44M) | (56.79M) | (45.39M) | (58.42M) | |
EPS (Basic) |
(5.20) | (10.50) | (5.44) | (3.54) | (2.03) | |
EPS (Basic) Growth |
- | -101.92% | 48.14% | 35.05% | 42.56% | |
Basic Shares Outstanding |
3.53M | 8.51M | 10.43M | 12.84M | 28.76M | |
EPS (Diluted) |
(5.20) | (10.50) | (5.44) | (3.54) | (2.03) | |
EPS (Diluted) Growth |
- | -101.92% | 48.14% | 35.05% | 42.56% | |
Diluted Shares Outstanding |
3.53M | 8.51M | 10.43M | 12.84M | 28.76M | |
EBITDA |
(17.29M) | (46.47M) | (45.26M) | (34.64M) | (52.51M) | |
EBITDA Growth |
- | -168.76% | 2.60% | 23.46% | -51.57% | |
EBITDA Margin |
- | - | - | - | -142.14% | NA |